PARP inhibitors have been successfully used in patients with breast or ovarian cancer who carry BRCA1/2 germline mutations (Litton et al. 2018; Robson et al. 2017; Weil et al. 2011). This evidence concerns the gene BRCA1 and ovarian cancer.